Anti-HIV agents. Using maraviroc in first-line therapy.
D000328:Adult; D000480:Alkynes; D048588:Benzoxazines / Q000009:adverse effects / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use*; D003521:Cyclopropanes; D005260:Female; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008055:Lipids / Q000097:blood; D008099:Liver / Q000201:enzymology; D008297:Male; D000077592:Maraviroc; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D019562:Viral Load
D000480:Alkynes; D048588:Benzoxazines; D003510:Cyclohexanes; D003521:Cyclopropanes; D023581:HIV Fusion Inhibitors; D008055:Lipids; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; C098320:efavirenz; D000077592:Maraviroc